<SEC-DOCUMENT>0001104659-16-091220.txt : 20160824
<SEC-HEADER>0001104659-16-091220.hdr.sgml : 20160824
<ACCEPTANCE-DATETIME>20160125171859
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-16-091220
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20160125

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TACTILE SYSTEMS TECHNOLOGY INC
		CENTRAL INDEX KEY:			0001027838
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		1331 TYLER STREET NE STE 200
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
		BUSINESS PHONE:		866-435-3948

	MAIL ADDRESS:	
		STREET 1:		1331 TYLER STREET NE STE 200
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="624" height="78" src="g160225bci001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.96%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jonathan R. Zimmerman</font></b></p>    </td>
<td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.04%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Faegre   Baker Daniels LLP</font></b></p>    </td>   </tr>
<tr>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.96%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Partner</font></i></p>    </td>
<td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.04%;">
<p align="right" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2200 Wells Fargo   Center </font><font face="Symbol">&#183;</font> 90 South Seventh   Street</p>    </td>   </tr>
<tr>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.96%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">jon.zimmerman@FaegreBD.com</font></b></p>    </td>
<td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.04%;">
<p align="right" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Minneapolis </font><font face="Symbol">&#183;</font>   Minnesota 55402-3901</p>    </td>   </tr>
<tr>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.96%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Direct <b>+1 612 766 8419</b></font></p>    </td>
<td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.04%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Phone <b>+1 612 766 7000</b></font></p>    </td>   </tr>
<tr>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.96%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.04%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax <b>+1 612 766 1600</b></font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">By EDGAR and Federal Express</font></u></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">January&nbsp;25, 2016</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amanda Ravitz</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Assistant Director</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">U.S. Securities and Exchange Commission</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Division of Corporation Finance</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">100 F Street, NE</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Washington, DC 20549</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Re:</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Tactile Systems Technology,&nbsp;Inc. (the &#147;<i>Company</i>&#148;)</b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Amendment No.&nbsp;2 to</font></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Draft Registration Statement on Form&nbsp;S-1</font></b></p>
<p style="margin:0in 0in .0001pt 1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Submitted December&nbsp;31, 2015</font></b></p>
<p style="margin:0in 0in .0001pt 1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CIK No.&nbsp;0001027838</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dear Ms.&nbsp;Ravitz:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On behalf of the Company, we are transmitting the following responses of the Company to the comments of the Securities and Exchange Commission&#146;s staff (the &#147;<i>Staff</i>&#148;) as set forth in the letter of Amanda Ravitz, dated January&nbsp;21, 2016 (the &#147;<i>Comment Letter</i>&#148;), to the revised Draft Registration Statement on Form&nbsp;S-1 submitted confidentially to the Securities and Exchange Commission on December&nbsp;31, 2015.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company is concurrently publicly filing via EDGAR a Registration Statement on Form&nbsp;S-1 (the &#147;<i>Registration Statement</i>&#148;).&#160; We have enclosed for your reference two courtesy copies of the Registration Statement in a version marked to show changes from the draft submitted confidentially on December&nbsp;31, 2015.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The responses herein were provided to this firm by the Company. In this letter, we have recited the comment from the Staff in italicized, bold type and have followed the comment with the Company&#146;s response in regular type.&#160; All references to page&nbsp;numbers in the Company&#146;s responses refer to page&nbsp;numbers in the Registration Statement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\rcheney\15-16022-5\task7745339\16022-5-bc.htm',USER='rcheney',CD='Jan 25 15:19 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Graphics</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">1.</font></i></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">It is not clear from the face of the graphic what is meant by &#147;Clinically Proven.&#148; Please revise to remove this language.</i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Company Response:</font></i></b> In response to the Staff&#146;s comment, the Company has removed the words &#147;Clinically Proven&#148; from this graphic.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our Competitive Strengths, page&nbsp;4</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">2.</font></i></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">We note your response to prior comment 3. However, please include disclosure that your system was not compared to an advanced pneumatic compression device in any of your clinical studies or advise.</i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Company Response:</font></i></b> In response to the Staff&#146;s comment, the Company has revised its disclosure on pages&nbsp;4 and 5 of the Registration Statement to disclose that the studies do not compare the Flexitouch System with other advanced pneumatic compression devices.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock-Based Compensation, page&nbsp;85</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">3.</font></i></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">In response to comment 6, you state that based on feedback received in 2015, you revised your original 2015 fair value determinations but did not adjust any prior periods. Please explain in more detail why you concluded that your original 2015 fair value determinations required revision, the nature of the feedback received, and how the changes impacted your original valuation methodologies. For example, explain if you revised assumptions or added additional valuation methodologies in determining the fair value of your common stock. Tell us why these changes to correct your 2015 valuations should not also be considered for prior period valuations.</i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Company Response:</font></i></b> As noted in the prior response, the Company historically utilized a market approach valuation method for its 2014 valuations and used a combination of the market approach valuation method and the income approach valuation method for its 2015 valuations.&#160; In 2015, the Company seriously considered the prospect of pursuing an initial public offering.&#160; At this time, the Company began interviewing investment banks to serve as underwriters in connection with a potential initial public offering process and, as 2015 progressed, the Company began working in earnest with the proposed lead underwriters to prepare for this proposed offering.&#160; In connection with these activities, the lead underwriters prepared a summary valuation of the Company to assist the board of directors as it considered whether to pursue the proposed offering.&#160; The summary valuation was provided based on the Company&#146;s performance through the second quarter of 2015 and was primarily a comparable company and comparable transaction review.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Based on this summary valuation, the Company reviewed its fair value determinations for 2015, effectively modifying its valuation approach for 2015 to include the summary valuation from the lead underwriters as a factor in determining fair value, along with the other approaches previously considered.&#160; Based on the information</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_021714_309"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\rcheney\15-16022-5\task7745339\16022-5-bc.htm',USER='rcheney',CD='Jan 25 15:19 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">received, the Company revised its fair value to $200 million for 2015 equity awards.&#160; The initial valuation performed as of December&nbsp;31, 2014, using the market approach valuation method and the income approach valuation method, did not consider the additional summary valuation provided by the lead underwriters.&#160; The Company&#146;s methodology effectively changed from the valuation methodology described previously in the draft registration statement to this three pronged analysis.&#160; Therefore, the Company made the conservative decision to use a $200 million fair value for awards granted in 2015.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company also considered whether to adjust the fair value for its 2014 equity awards.&#160; The Company noted that it had received no summary valuation from the lead underwriters in 2014 and it had not actively considered an initial public offering throughout 2014.&#160; In addition, 304,000 of the 441,500 stock options granted in 2014 were granted on January&nbsp;22, 2014, and 62,500 were granted on June&nbsp;17, 2014.&#160; These awards were made over a year prior to the summary valuation received in 2015.&#160; Since no summary valuation was undertaken in 2014, 83% of the options granted in 2014 were granted in the first half of the year and the Company&#146;s performance had materially improved from 2014 to 2015 when the valuation feedback was received (revenue growth of 40% in the first six months of 2015 as compared to 2014), the Company did not make any changes to its 2014 common stock fair value or prior periods.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">4.</font></i></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">Further, to help explain the reasonableness of the increase in your valuation from 2014 to 2015 please address the following:</i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">Tell us why the increase in your revenues during 2014 did not result in an increasing valuation during this period. We note that you valued your common stock at the same amount for all 2014 grants.</i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">Tell us why it was reasonable to use different valuation methodologies and different comparable companies for the 2014 grants versus 2015 grants.</i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">Tell us why it was reasonable to use a valuation report as of September&nbsp;30, 2013 to value all of your grants in 2014 and use a valuation report as of December&nbsp;31, 2014 to value all of your grants in 2015.</i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Company Response:</font></i></b>&#160; The Company utilized the valuation methodologies outlined previously to determine the fair value of the Company&#146;s common stock as $0.34 as of September&nbsp;30, 2013.&#160; The Company&#146;s board of directors noted that the Company&#146;s revenues were anticipated to increase, and did increase organically during 2014; therefore, the board of directors increased its common stock fair value to $0.48 for 2014, which was a 41% increase over the fair value determined on September&nbsp;30, 2013.&#160; The Company&#146;s stock option awards in 2014 were 304,000 on January&nbsp;22, 2014, 62,500 on June&nbsp;17, 2014 and 75,000 on September&nbsp;23, 2014.&#160; All of these stock options were granted with an exercise price of $0.48.&#160; The Company believes it is reasonable to use a September&nbsp;30, 2013 valuation report to value its 2014 stock option grants, because the board of directors</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_021746_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\rcheney\15-16022-5\task7745339\16022-5-bc.htm',USER='rcheney',CD='Jan 25 15:19 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">did increase the fair value of the common stock by 41%, based on increasing revenues and because the majority of the stock options were issued in January&nbsp;and June&nbsp;2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company reviews its valuation methodologies and comparable companies prior to the preparation of each valuation report or when events occur that indicate a change may be necessary.&#160; For the December&nbsp;31, 2014 valuation report, the Company updated its comparable company mix as the size of the Company had increased and its product base was more diversified.&#160; The Company historically reconsiders its comparable company mix to ensure it is using a mix that the board of directors believes provides high quality comparable companies to the Company at the time the analysis is performed.&#160; In addition, for the December&nbsp;2014 report, the Company considered the methodology utilized in 2014 and determined it was appropriate to add the income approach (i.e. discounted cash flow analysis) to the methodologies utilized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For 2015 stock option grants, the Company granted awards with a $1.50 exercise price, a 17% premium to the $1.28 common stock valuation as of December&nbsp;31, 2014.&#160; However, as noted above, the market price of the Company&#146;s common stock used in the calculation of stock option compensation expense was revised to $4.00 (a $200 million fair value for the Company) as a result of events that occurred during 2015 and which were not considered in the December&nbsp;31, 2014 common stock valuation.&#160; The revised fair value was used for all stock option grants in 2015 because all 473,000 stock option grants in 2015 were granted between February&nbsp;2, 2015 and June&nbsp;24, 2015, with 72% of them being granted on February&nbsp;2, 2015.&#160; For 2014 stock option grants, the same fair value was used to value all options because 83% of the options were granted in the first half of the year (304,000 or 69% on January&nbsp;22, 2014 and 62,500 or14% on June&nbsp;17, 2014).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">5.</font></i></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">Also, please revise your disclosure beginning on page&nbsp;87 to be consistent with the description of how you valued your common stock in your response.</i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Company Response:</font></i></b>&#160; In response to the Staff&#146;s comment, the Company has revised its disclosure beginning on page&nbsp;87 of the Registration Statement to be consistent with the description of how the Company valued its common stock that was contained in its response letter to the Staff dated December&nbsp;31, 2015.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Impact on Clinical Outcomes and Healthcare Costs with Use of our Flexitouch System, page&nbsp;99</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">6.</font></i></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">We note your response to prior comment 8. However, it is unclear what treatment each patient received during that 12 month period before receiving your device, e.g., no treatment, treatment using a particular device for the entire 12 months, or some form of treatment between the two. Please revise to include that information or advise.</i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Company Response:</font></i></b> In response to the Staff&#146;s comment, the Company has revised its disclosure on page&nbsp;100 of the Registration Statement to indicate that patients were excluded from the study if they had a claim for a pneumatic compression device during the prior 12 month period.&#160; Because the study excluded patients based on claims, the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="PB_4_021803_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\rcheney\15-16022-5\task7745339\16022-5-bc.htm',USER='rcheney',CD='Jan 25 15:19 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Company is not able to determine whether, or the extent to which, patients used any device, but did not submit a claim for one, during the 12 month period before receiving the Flexitouch System.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Third-Party Reimbursement, page&nbsp;117</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">7.</font></i></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">Please revise this section to reflect your response to prior comment 4.</i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Company Response:</font></i></b> In response to the Staff&#146;s comment, the Company has revised its disclosure on page&nbsp;118 of the Registration Statement to disclose that it believes that future expenses related to its efforts to overturn the Local Coverage Determination will not be material, and that it will use cash on hand to fund such expenses.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">8.</font></i></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">It appears that you have not disclosed the specific time frame for the required trial of conservative therapy for all patients under the new Local Coverage Determination as your response to prior comment 10 suggests. Please revise.</i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Company Response:</font></i></b> In response to the Staff&#146;s comment, the Company has revised its disclosure on pages&nbsp;16 and 118 of the Registration Statement to disclose that the specific time frame for the required trial of conservative therapy for patients under the new Local Coverage Determination is four consecutive weeks of conservative therapy with no significant symptom improvement in symptoms during any of those four weeks.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Please do not hesitate to call me at (612) 766-8419 if you have any questions or comments regarding the foregoing or if we can be of service in facilitating your review of this filing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sincerely,</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">/s/ Jonathan R.   Zimmerman</font></i></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jonathan   R. Zimmerman</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Enclosures</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="PB_5_021909_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\rcheney\15-16022-5\task7745339\16022-5-bc.htm',USER='rcheney',CD='Jan 25 15:19 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">cc:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tactile Systems Technology,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gerald R. Mattys, Chief Executive Officer</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Robert J. Folkes, Chief Operating Officer and Chief Financial Officer</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Faegre Baker Daniels LLP</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Christine G. Long</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Dorsey&nbsp;&amp; Whitney LLP</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jonathan B. Abram</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Peter B. Skrief</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Grant Thornton LLP</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Greg Steiner</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="PB_6_021931_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\rcheney\15-16022-5\task7745339\16022-5-bc.htm',USER='rcheney',CD='Jan 25 15:19 2016' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g160225bci001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g160225bci001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !. G # 2(  A$! Q$!_\0
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M "BBB@ HHHH *\D\&^&$\5?VM/>ZIJD307KQJ(;D@8Z]\^M>MUX_X*TKQ!J
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M5JO_ #\6_P#WQ6C10!G>5JO_ #\6_P#WQ1Y6J_\ /Q;_ /?%:-% &=Y6J_\
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M5JO_ #\6_P#WQ1Y6J_\ /Q;_ /?%:-% &=Y6J_\ /Q;_ /?%'E:K_P _%O\
M]\5HT4 9WE:K_P _%O\ ]\4>5JO_ #\6_P#WQ6C10!G>5JO_ #\6_P#WQ1Y6
MJ_\ /Q;_ /?%:-% &=Y6J_\ /Q;_ /?%'E:K_P _%O\ ]\5HT4 9WE:K_P _
M%O\ ]\4>5JO_ #\6_P#WQ6C10!G>5JO_ #\6_P#WQ1Y6J_\ /Q;_ /?%:-%
M&=Y6J_\ /Q;_ /?%'E:K_P _%O\ ]\5HT4 9WE:K_P _%O\ ]\4>5JO_ #\6
M_P#WQ6C10!G>5JO_ #\6_P#WQ1Y6J_\ /Q;_ /?%:-% &=Y6J_\ /Q;_ /?%
M'E:K_P _%O\ ]\5HT4 9WE:K_P _%O\ ]\4>5JO_ #\6_P#WQ6C10!G>5JO_
M #\6_P#WQ1Y6J_\ /Q;_ /?%:-% &=Y6J_\ /Q;_ /?%*(M4W#-Q!C//RUH4
$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
